You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The agreement covers 43 million people in the US and includes Sequenom's MaterniT21 Plus and HerediT CF and Universal tests.
The agreements with the PPOs bring the total number of Americans with covered access to Biocept's tests to about 31 million.
Starting Sept. 15, Cologuard will be available to BCBS' 500,000 members through their physicians without a co-payment or co-insurance.
The contracts with Stratose, Three Rivers Provider Network, and Fortified Provider Network provide coverage for Opko's testing services.
The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
Through the arrangement, Paradigm's test, which sequences both DNA and RNA, will be available to the more than 15 million US members in Three River's network.
The tool is aimed at facilitating a simple and efficient process that payors can use to asses a CDx's value and if further technology assessments are warranted.
Stratose and Paradigm have inked a deal providing Stratose's members access to the PCDx test, which uses NGS technology to identify genomic and proteomic mutations.
Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.
Nature News reports on how meeting cancellations and related costs are affecting scientific societies.
In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.
COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.
In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.